Literature DB >> 18344552

Analgesic effectiveness of caudal levobupivacaine and ketamine.

B G Locatelli1, G Frawley, A Spotti, P Ingelmo, S Kaplanian, B Rossi, L Monia, V Sonzogni.   

Abstract

BACKGROUND: Ketamine is used increasingly in paediatric anaesthetic practice to prolong the action of a caudal block. This study was designed to determine if adding S(+)-ketamine 0.5 mg kg(-1) allows a lower concentration of levobupivacaine to be used for caudal anaesthesia without loss of clinical effectiveness.
METHODS: One hundred and sixty-four children (ASA I or II) aged 3 months-6 yr were randomly allocated to receive 1 ml kg(-1) of levobupivacaine 0.15% with 0.5 mg kg(-1) S(+)-ketamine (Group 1), levobupivacaine 0.175% with 0.5 mg kg(-1) S(+)-ketamine (Group 2), or levobupivacaine 0.2% (Group 3) by the caudal route. Pain, motor block, sedation, and requirement for postoperative analgesia were assessed up to 6 h after operation.
RESULTS: There was no significant difference between the groups in effectiveness at first surgical incision. Significantly lower analgesic requirements were reported in Group 2 compared with Group 3 at wakeup, 180 and 360 min after operation. Time to first rescue analgesia was longer in Group 2 compared with Group 1 or 3. Kaplan-Meier survival analysis of analgesia free time demonstrated a significant advantage of Group 2 over Groups 1 and 3 (log rank P=0.05). The incidence of postoperative motor block was not significantly different between the groups. No excess sedation or dysphoric reactions were observed in the ketamine groups.
CONCLUSIONS: The addition of 0.5 mg kg(-1) S(+)-ketamine to levobupivacaine 0.175% for caudal analgesia for lower abdominal and urological surgery is significantly more effective in providing postoperative analgesia than levobupivacaine 0.15% with 0.5 mg kg(-1) S(+)-ketamine or levobupivacaine 0.2%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344552     DOI: 10.1093/bja/aen048

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  8 in total

1.  Effects of intrathecal ketamine in the neonatal rat: evaluation of apoptosis and long-term functional outcome.

Authors:  Suellen M Walker; B David Westin; Ronald Deumens; Marjorie Grafe; Tony L Yaksh
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

Review 2.  Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data.

Authors:  Suellen M Walker; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine.

Authors:  Chantal A A Heppolette; Derek Brunnen; Sohail Bampoe; Peter M Odor
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

4.  Acute pain management in children.

Authors:  Susan T Verghese; Raafat S Hannallah
Journal:  J Pain Res       Date:  2010-07-15       Impact factor: 3.133

5.  Caudal additives do not improve the analgesia afforded by levobupivacaine after hypospadias repair.

Authors:  Kay Davies; Graham Wilson; Thomas Engelhardt
Journal:  Anesth Pain Med       Date:  2012-01-01

6.  The success rate and complications of awake caudal epidural bupivacaine alone or in combination with intravenous midazolam and ketamine in pre-term infants.

Authors:  Mahin Seyedhejazi; Majed Mashhoori; Rasoul Azarfarin; Daryoush Shekhzadeh; Nasrin Taghizadieh
Journal:  Afr J Paediatr Surg       Date:  2015 Oct-Dec

7.  Dexmedetomidine and Ketamine as an Adjuvant to Levobupivacaine for Pediatric Caudal Analgesia: A Randomized, Controlled Study.

Authors:  Ganesh K Ram; Prakash K Dubey; P Akhileshwar; Alok Ranjan
Journal:  Anesth Essays Res       Date:  2020-10-12

8.  Transversus Abdominis Plane (TAP) Block: A Comparative Study between Levobupivacaine versus Levobupivacaine plus Ketamine in Abdominoplasty.

Authors:  Radwa F Mansour; Mohamed A Afifi; Mohamed S Abdelghany
Journal:  Pain Res Manag       Date:  2021-10-31       Impact factor: 3.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.